News
-
ACLA Urges Congressional Leaders to Advance New Regulatory Framework for Diagnostic Tests
In Comments to Congress, ACLA Cites Concerns with the FDA’s New Proposals for Diagnostic Reform Washington, D.C. – Today, the American Clinical Laboratory Association (ACLA) calls on Congressional leaders to enact a distinct regulatory framework for diagnostics – a key goal outlined in comments to Reps. Larry Bucshon (R-IN) and Diana DeGette (D-CO), and Sens. Orrin Hatch (R-UT) and Michael Bennet (D-CO). The commentsContinue Reading »... -
ACLA Comments on FDA Technical Assistance on the Diagnostic Accuracy and Innovation Act
... -
When Rhetoric Doesn’t Match Reality – Why Claims of Overutilization Ignore the Real Dollar Signs
Today, decades of medical progress have contributed to a sea change in how we treat the most serious and complex health issues. We’ve seen ground-breaking innovations that allow us to identify diseases like cancer and HIV-AIDS and intervene with targeted, comprehensive care plans. Laboratory tests are the starting point for this next generation of care delivery. While much attention has been paid to theContinue Reading »... -
Diagnostic Reform Coalition Letter to the Hill regarding FDA Technical Assistance
... -
Leading Patient, Provider, Diagnostic and Laboratory Organizations Call on Congress to Protect Seniors from Medicare Lab Cuts
HHS’ flawed data collection system jeopardizes beneficiary access to critical lab services Washington, D.C. – With millions of Medicare beneficiaries facing year-over-year cuts to their Medicare lab access, more than 30 leading organizations representing patients, health care professionals, laboratories and diagnostic manufacturers urged Congressional leaders to take immediate action to prevent drastic reductions to beneficiaries’ care. The letter reiterates the serious concerns regarding theContinue Reading »... -
PAMA Stakeholder Letter to Congress
... -
Market-Based in Practice, Not Just Theory
One of the driving forces in today’s health system is the goal of promoting and maintaining a competitive market for patients. In a “market-based” health system, consumers see the direct benefit of labs competing on quality, cost and services available – rather than an arbitrary, one-size-fits-all approach that fails to achieve any of these goals. In fact, that was one of the prevailing incentivesContinue Reading »... -
ACLA Statement on HHS OIG Report Regarding PAMA Cuts & Data Collection
Washington, D.C. – Following the release of today’s report from the U.S. Department of Health & Human Services (HHS) and the Office of Inspector General (OIG) regarding laboratory data collection under The Protecting Access to Medicare Act of 2014 (PAMA), Julie Khani, President of the American Clinical Laboratory Association (ACLA), released the following statement: “Today’s OIG report skirts the central issue: that HHS deliberatelyContinue Reading »... -
AIM Coalition Urges Policymakers to Strengthen Medicare Self-Referral Provisions to Advance Transition to Value-Based Care
Washington, D.C. – As policymakers explore solutions to further advance the transition to a value-based care delivery system, members of the Alliance for Integrity in Medicare (AIM), a broad coalition of medical specialty, laboratory, radiation oncology and medical imaging groups committed to ending the practice of inappropriate physician self-referral, issued the following statement ahead of a Ways and Means Health Subcommittee hearing on theContinue Reading »... -
ACLA Statement on Proposed 2019 Medicare Payment Changes
Proposed rule seeks input on how to improve data collection process; millions of seniors still at risk for continued cuts to essential Medicare lab services Washington, D.C. – Following the release of a proposed Medicare payment rule, The American Clinical Laboratory Association (ACLA) continues to raise concerns about the flawed implementation of the Protecting Access to Medicare Act (PAMA) that will lead toContinue Reading »...
